Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is set to release its earnings data after the market closes on Tuesday, July 25th. Analysts expect Vertex Pharmaceuticals to post earnings of $0.36 per share for the quarter.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.09. Vertex Pharmaceuticals had a net margin of 34.92% and a return on equity of 74.81%. The business had revenue of $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. During the same quarter in the previous year, the firm posted $0.09 EPS. The firm’s revenue was up 79.5% on a year-over-year basis. On average, analysts expect Vertex Pharmaceuticals to post $1.68 EPS for the current fiscal year and $3.19 EPS for the next fiscal year.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 129.21 on Tuesday. The firm has a 50-day moving average of $123.78 and a 200-day moving average of $101.21. The company has a market cap of $32.18 billion, a P/E ratio of 180.21 and a beta of 1.73. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $137.26.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 157,200 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $119.50, for a total transaction of $18,785,400.00. Following the completion of the sale, the chief executive officer now directly owns 395,152 shares in the company, valued at $47,220,664. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Paul M. Silva sold 2,577 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $133.36, for a total transaction of $343,668.72. Following the sale, the senior vice president now owns 22,648 shares of the company’s stock, valued at $3,020,337.28. The disclosure for this sale can be found here. Insiders have sold 404,097 shares of company stock worth $50,604,479 over the last ninety days. 1.80% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Scheduled to Post Earnings on Tuesday” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/18/vertex-pharmaceuticals-incorporated-vrtx-scheduled-to-post-earnings-on-tuesday.html.

A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $102.00 price target on the stock in a research note on Tuesday, March 28th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, April 30th. Vetr upgraded shares of Vertex Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $102.09 price target on the stock in a research note on Monday, May 15th. Cowen and Company restated a “market perform” rating and set a $75.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, March 30th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, April 28th. Eight equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $122.72.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Earnings History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.